Iomai - Worst Pharma Stocks of 2007

Company: Iomai
Starting stock price: $4.85
Ending stock price: $1.03
Percent Change: -78.76%

Details: Iomai reported in May that it's needle-free flu vaccine demonstrated less of an immune response than an injection, sending its stock down 35%. The company is also developing a patch for traveler's diarrhea that has delivered promising results, and is working on two immunostimulant patches for pandemic flu.

More News:
Iomai vax patch guards against traveler's diarrhea. Report
Vaccine-maker Iomai files $83M IPO. Report

Iomai - Worst Pharma Stocks of 2007
Read more on

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.